Our Science

A healthy immune system protects the host against harmful antigens (pathogenic microbes, toxic irritants) while maintaining tolerance to innocuous ones (body's own and microbiota). Such fine antigenic distinctions are however lost in diseases such as autoimmunity, allergy and chronic inflammation.

So far biomedical science has been unable to capitalize on the two fundamental attributes of the adaptive immune system, namely antigen-specificity and memory. In addition to being variably effective, most immunotherapies introduced thus far such as antibodies to TNF-α, CD3, CD20, IgE Fc region, CTLA-4, PD1/PDL1 are non-specific and lack a long-term effect.

At Tregeutix we believe that existing translational gap in antigen-specific immunotherapies stems from a fundamental failure to understand how Tregs utilize antigen cross-reactivity to coordinate antigen-specific immune responses. Our research led to the development of a novel discovery framework dubbed SPIRAL that reveals that contrary to prevailing dogma, thymic Foxp3+ Tregs and cross-reactive antigen-expressing commensal microbiota co-evolved to regulate both tolerance to cryptic auto-antigens and allergens as well as to focus effective immunity to natural infection or vaccines and tumors in an antigen-specific manner.

At Tregeutix we are committed to advancing the field of antigen-specific immunotherapy by investing in proof-of-concept research to harness the full predictive potential of SPIRAL and accelerate development of highly effective Treg-based antigen-specific immunotherapeutics we refer to as tregeutics.